PRT13722

PRT13722 is a first-in-class, highly potent, and orally bioavailable small molecule **targeted protein degrader (PROTAC)** that selectively targets **Histone acetyltransferase KAT6A** (also known as MOZ) for degradation. Developed by **Prelude Therapeutics**, PRT13722 is designed to treat **ER+/HER2- breast cancer** and other **KAT6A-amplified** malignancies, such as lung cancer. By selectively degrading KAT6A while sparing the closely related KAT6B and KAT7 proteins, PRT13722 aims to achieve robust anti-tumor efficacy with a significantly improved safety profile, particularly regarding hematologic toxicities like neutropenia, which are commonly associated with non-selective KAT6A/B inhibitors. Preclinical studies have demonstrated that PRT13722 suppresses cell proliferation in models resistant to endocrine therapy and CDK4/6 inhibitors. As of early 2026, the compound is a development candidate with an Investigational New Drug (IND) filing anticipated in mid-2026.

Other names

KAT6A selective degraderKAT-6A selective degraderKAT 6A selective degraderKAT6A degraderKAT-6A degraderKAT 6A degrader